Pembrolizumab-Induced Hypothyroidism: A Case Report
Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarc...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-07, Vol.15 (7), p.e41889 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e41889 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Gaibor, Carlos Das, Rohan Reddy, Vijayakumari |
| description | Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage. |
| doi_str_mv | 10.7759/cureus.41889 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10348603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2844014146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c267t-5afc33cac3f3d9a19255aaa31b446e4b3acdab02e9a216f295d4468e65e3c0b63</originalsourceid><addsrcrecordid>eNpVkMFLwzAYxYMobszdPEvBq51Jk7SpFxlD3WCgiJ7DlzR1HWtTk1aof72dm2Oevg_e473HD6FLgidJwtNb3TrT-gkjQqQnaBiRWISCCHZ69A_Q2Ps1xpjgJMIJPkcDmjCexAQPEX0xpXJ2U3y3JahwUWWtNlkw72rbrDpni6zw5V0wDWbgTfBqauuaC3SWw8ab8f6O0Pvjw9tsHi6fnxaz6TLUUZw0IYdcU6pB05xmKZA04hwAKFGMxYYpCjoDhSOTQr81j1Ke9YIwMTdUYxXTEbrf5datKk2mTdU42MjaFSW4Tloo5H-lKlbyw35JgikTMaZ9wvU-wdnP1vhGrm3rqn60jARjmDDCtj03O5d21ntn8kMFwXKLWe4wy1_Mvf3qeNbB_AeV_gCaLnoa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2844014146</pqid></control><display><type>article</type><title>Pembrolizumab-Induced Hypothyroidism: A Case Report</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Gaibor, Carlos ; Das, Rohan ; Reddy, Vijayakumari</creator><creatorcontrib>Gaibor, Carlos ; Das, Rohan ; Reddy, Vijayakumari</creatorcontrib><description>Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.41889</identifier><identifier>PMID: 37457610</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Blood ; Case reports ; Creatinine ; Endocrinology ; Endocrinology/Diabetes/Metabolism ; Fractures ; Hemoglobin ; Hypothyroidism ; Immunotherapy ; Internal Medicine ; Lung cancer ; Medical imaging ; Monoclonal antibodies ; Myasthenia gravis ; Oncology ; Potassium ; Proteins ; Targeted cancer therapy ; Thyroid gland</subject><ispartof>Curēus (Palo Alto, CA), 2023-07, Vol.15 (7), p.e41889</ispartof><rights>Copyright © 2023, Gaibor et al.</rights><rights>Copyright © 2023, Gaibor et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Gaibor et al. 2023 Gaibor et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c267t-5afc33cac3f3d9a19255aaa31b446e4b3acdab02e9a216f295d4468e65e3c0b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348603/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348603/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37457610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gaibor, Carlos</creatorcontrib><creatorcontrib>Das, Rohan</creatorcontrib><creatorcontrib>Reddy, Vijayakumari</creatorcontrib><title>Pembrolizumab-Induced Hypothyroidism: A Case Report</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage.</description><subject>Blood</subject><subject>Case reports</subject><subject>Creatinine</subject><subject>Endocrinology</subject><subject>Endocrinology/Diabetes/Metabolism</subject><subject>Fractures</subject><subject>Hemoglobin</subject><subject>Hypothyroidism</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Medical imaging</subject><subject>Monoclonal antibodies</subject><subject>Myasthenia gravis</subject><subject>Oncology</subject><subject>Potassium</subject><subject>Proteins</subject><subject>Targeted cancer therapy</subject><subject>Thyroid gland</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkMFLwzAYxYMobszdPEvBq51Jk7SpFxlD3WCgiJ7DlzR1HWtTk1aof72dm2Oevg_e473HD6FLgidJwtNb3TrT-gkjQqQnaBiRWISCCHZ69A_Q2Ps1xpjgJMIJPkcDmjCexAQPEX0xpXJ2U3y3JahwUWWtNlkw72rbrDpni6zw5V0wDWbgTfBqauuaC3SWw8ab8f6O0Pvjw9tsHi6fnxaz6TLUUZw0IYdcU6pB05xmKZA04hwAKFGMxYYpCjoDhSOTQr81j1Ke9YIwMTdUYxXTEbrf5datKk2mTdU42MjaFSW4Tloo5H-lKlbyw35JgikTMaZ9wvU-wdnP1vhGrm3rqn60jARjmDDCtj03O5d21ntn8kMFwXKLWe4wy1_Mvf3qeNbB_AeV_gCaLnoa</recordid><startdate>20230714</startdate><enddate>20230714</enddate><creator>Gaibor, Carlos</creator><creator>Das, Rohan</creator><creator>Reddy, Vijayakumari</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20230714</creationdate><title>Pembrolizumab-Induced Hypothyroidism: A Case Report</title><author>Gaibor, Carlos ; Das, Rohan ; Reddy, Vijayakumari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c267t-5afc33cac3f3d9a19255aaa31b446e4b3acdab02e9a216f295d4468e65e3c0b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Blood</topic><topic>Case reports</topic><topic>Creatinine</topic><topic>Endocrinology</topic><topic>Endocrinology/Diabetes/Metabolism</topic><topic>Fractures</topic><topic>Hemoglobin</topic><topic>Hypothyroidism</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Medical imaging</topic><topic>Monoclonal antibodies</topic><topic>Myasthenia gravis</topic><topic>Oncology</topic><topic>Potassium</topic><topic>Proteins</topic><topic>Targeted cancer therapy</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaibor, Carlos</creatorcontrib><creatorcontrib>Das, Rohan</creatorcontrib><creatorcontrib>Reddy, Vijayakumari</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaibor, Carlos</au><au>Das, Rohan</au><au>Reddy, Vijayakumari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pembrolizumab-Induced Hypothyroidism: A Case Report</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-07-14</date><risdate>2023</risdate><volume>15</volume><issue>7</issue><spage>e41889</spage><pages>e41889-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Pembrolizumab is a monoclonal antibody frequently used as immunotherapy for lung cell carcinoma that has been reported to cause hypothyroidism and myasthenia gravis among other, unwanted side effects. Here, we present an interesting case of a 77-year-old male previously diagnosed with lung adenocarcinoma managed with pembrolizumab. Initially, he was admitted after a mechanical fall sustaining a facial laceration and subacute fracture in the nasal bone. However, during the workup, thyroid-stimulating hormone (TSH) was found to be elevated, which was attributed to the history of pembrolizumab usage.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37457610</pmid><doi>10.7759/cureus.41889</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-07, Vol.15 (7), p.e41889 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10348603 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Blood Case reports Creatinine Endocrinology Endocrinology/Diabetes/Metabolism Fractures Hemoglobin Hypothyroidism Immunotherapy Internal Medicine Lung cancer Medical imaging Monoclonal antibodies Myasthenia gravis Oncology Potassium Proteins Targeted cancer therapy Thyroid gland |
| title | Pembrolizumab-Induced Hypothyroidism: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A12%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pembrolizumab-Induced%20Hypothyroidism:%20A%20Case%20Report&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Gaibor,%20Carlos&rft.date=2023-07-14&rft.volume=15&rft.issue=7&rft.spage=e41889&rft.pages=e41889-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.41889&rft_dat=%3Cproquest_pubme%3E2844014146%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2844014146&rft_id=info:pmid/37457610&rfr_iscdi=true |